dr. richard saul, a behavioral neurologist who has been practicing for 50 years.im in just a moment's time. you can see him on the screen. first, this story has major business implications as well. sheila dharmarajan reports on the big business of treating adhd. >> i will let you talk to the doctors about whether adhd actually exists or not but there's no argument that it is big money for big pharma. cdc data actually shows that adhd diagnosis has been made in 15% of high school children and if you look at the number of children who are on medication for it now, we are now at the 3.5 million mark. that's up from just 600,000 in 1990. when you look at sales of stimulant drugs used to treat these children, now, $9 billion, more than five times than just a decade ago. when you talk about players in this space, you talk about scheier pharmaceuticals, the company's number one drug by sales has seen sales nearly double over the past five years. even adderall which raked in nearly $200 million. you talk about novartis with its ritalin drug. another player in the sector w